Three Columbus Circle
15th Floor
New York, NY 10019
United States
646 427 2727
https://indaptusrx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Jeffrey A. Meckler | CEO & Director | 888.32k | N/D | 1967 |
Mr. Walt Addison Linscott Esq. | Chief Operating Officer | 666.63k | N/D | 1961 |
Dr. Michael J. Newman Ph.D. | Founder, Chief Scientific Officer & Director | 468.82k | N/D | 1957 |
Mr. Nir Sassi | CFO, Secretary & Treasurer | 378.47k | N/D | 1976 |
Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer | N/D | N/D | 1969 |
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
La calificación ISS Governance QuickScore de Indaptus Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.